CD137<sup>+</sup> T-Cells: Protagonists of the Immunotherapy Revolution
The CD137 receptor (4-1BB, TNF RSF9) is an activation induced molecule expressed by antigen-specific T-cells. The engagement with its ligand, CD137L, is capable of increasing T-cell survival, proliferation, and cytokine production. This allowed to identify the CD137<sup>+</sup> T-cells a...
Main Authors: | Alessio Ugolini, Marianna Nuti |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-01-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/3/456 |
Similar Items
-
An Update on Anti-CD137 Antibodies in Immunotherapies for Cancer
by: Dinh-Toi Chu, et al.
Published: (2019-04-01) -
Circulating CD137<sup>+</sup> T Cell Levels Are Correlated with Response to Pembrolizumab Treatment in Advanced Head and Neck Cancer Patients
by: Alessio Cirillo, et al.
Published: (2023-04-01) -
Ecological Half-Life of <sup>137</sup>Cs in Fish
by: Nataliia Zarubina, et al.
Published: (2023-07-01) -
Ecological Half-Life of <sup>137</sup>Cs in Fungi
by: Nataliia E. Zarubina, et al.
Published: (2022-12-01) -
The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy
by: Christina Claus, et al.
Published: (2023-12-01)